WallStSmart

Thermo Fisher Scientific Inc (TMO)vsExagen Inc (XGN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 66826% more annual revenue ($44.56B vs $66.58M). TMO leads profitability with a 15.0% profit margin vs -30.0%. TMO earns a higher WallStSmart Score of 59/100 (C).

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9

XGN

Hold

36

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Intrinsic value data unavailable for XGN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

XGN1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
21.8%8/10

Revenue surging 21.8% year-over-year

Areas to Watch

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

XGN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$65.91M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-147.8%2/10

ROE of -147.8% — below average capital efficiency

Free Cash FlowQuality
$-3.06M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : XGN

The strongest argument for XGN centers on Revenue Growth. Revenue growth of 21.8% demonstrates continued momentum.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : XGN

The primary concerns for XGN are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

TMO profiles as a value stock while XGN is a growth play — different risk/reward profiles.

XGN carries more volatility with a beta of 1.91 — expect wider price swings.

XGN is growing revenue faster at 21.8% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (59/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Exagen Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.

Want to dig deeper into these stocks?